

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

**VOLUNTARY ANNOUNCEMENT
SUCCESSFUL COMPLETION OF U.S. FDA PRE-LICENSE INSPECTION
(PLI) FOR HEPCLUDEX® API**

This announcement is made by Medtide Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the current Good Manufacturing Practice (“**cGMP**”) manufacturing facility in Hangzhou, China, of Chinese Peptide Company (“**Chinese Peptide**”), a wholly owned subsidiary of the Company, has successfully completed a Pre-License Inspection (“**PLI**”) conducted by the U.S. Food and Drug Administration (“**FDA**”).

The rigorous onsite audit, conducted from January 26 to February 3, 2026, comprehensively evaluated the facility’s commercial manufacturing operations for the complex, fully synthetic long-chain peptide active pharmaceutical ingredient (“**API**”) of Hepcludex® (bulevirtide-gmod) 8.5mg for injection, which received accelerated approval from the U.S. FDA on May 22, 2026, as the first and only approved treatment for chronic hepatitis delta virus (“**HDV**”) infection in the United States (“**U.S.**”).

“Following the landmark U.S. FDA accelerated approval of Hepcludex®, Chinese Peptide Company extends our warmest and most sincere congratulations to our strategic partner, Gilead Sciences,” said Dr. Li Xiang, Chairman of Chinese Peptide Company. “As the commercial API supplier for this pioneering therapy, we are immensely proud to witness and support this historic medical advancement that may potentially alter the treatment landscape for patients with chronic HDV.”

About Chronic HDV

HDV infection occurs exclusively as a co-infection in individuals living with the hepatitis B virus (“**HBV**”). Chronic HDV is clinically recognized as the most severe and rapidly progressive form of viral hepatitis. Compared with HBV infection alone, HDV co-infection accelerates the disease progression, carrying a markedly higher risk of rapid progression toward severe liver fibrosis (scarring), cirrhosis, liver failure, liver cancer, and mortality.

In the U.S., studies in general populations estimate that HDV affects between 2% and 4% of individuals with chronic HBV, representing approximately 40,000 to 80,000 people living with this devastating condition. Due to historically low screening rates and limited clinical pathways, patients face the immense complexity of managing two distinct viral liver diseases simultaneously. Prior to the accelerated approval of Hepcludex® (bulevirtide-gmod), there were no FDA-approved therapies available, leaving a critical gap in care. The landmark approval of Hepcludex® addresses this profound unmet medical need, marking a historic milestone that has the potential to fundamentally alter the clinical course of HDV for patients in the U.S..

About Chinese Peptide Company

Chinese Peptide, a wholly owned subsidiary of the Company, is a peptide and oligonucleotide-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”), offering full-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production. Chinese Peptide was founded in 2001 and is headquartered in Hangzhou, China, with its international headquarter located in California, USA. It has commercial production sites and offices in both China and the U.S. With over 25 years of experience in peptide API development and GMP manufacturing, the company serves more than 1,000 pharmaceutical and biotechnology clients across 50+ countries and regions worldwide. The company operates metric-ton scale GMP manufacturing capacity, and its manufacturing facilities have successfully passed GMP inspections conducted by multiple regulatory authorities and quality organizations, including the U.S. FDA, National Medical Products Administration, Therapeutic Goods Administration and European Medicines Agency, underscoring the company’s consistent compliance with international quality and manufacturing standards.

About the Company

The Company is a leading, publicly listed global CRDMO that officially listed on the main board of The Stock Exchange of Hong Kong Limited in 2025. Strategically leveraging its vertically integrated platform, proprietary technology engines, and advanced manufacturing infrastructure across the U.S. and China, the Company is dedicated to accelerating the development and sustainable commercial supply of advanced peptide and oligonucleotide therapeutics worldwide.

By order of the Board

Medtide Inc.

泰德醫藥(浙江)股份有限公司

Dr. Xu Qi

Chairwoman and Chief Executive Officer

Hong Kong, July 31, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).